Bladder Cancer Clinical Trials

Find Bladder Cancer Clinical Trials Near You

A Predictive Model for Recurrence and Progression Risk After TURBT for Bladder Cancer on Intraoperative Irrigation Fluid Absorption Volume and Perioperative cfDNA Levels

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

This prospective observational cohort study aims to evaluate the association between intraoperative irrigation fluid absorption and perioperative cell-free DNA (cfDNA) dynamics in patients undergoing transurethral resection of bladder tumor (TURBT). Eligible patients with suspected or confirmed bladder cancer scheduled for TURBT will be enrolled. Intraoperative irrigation fluid absorption volume will be recorded, and peripheral blood samples will be collected before surgery and within 24 hours after surgery for cfDNA extraction and mutation analysis. The study will assess whether irrigation fluid absorption volume is associated with changes in cfDNA concentration, tumor-related mutation detection, and clinicopathological features, including tumor stage, grade, size, number, invasion depth, concomitant carcinoma in situ, operative time, resection depth, and intraoperative blood loss. Patients will also be followed for postoperative recurrence, progression, metastasis, and other adverse oncological outcomes. This study may provide preliminary evidence for understanding perioperative tumor-related molecular changes during TURBT and may help improve risk stratification, perioperative management, and postoperative follow-up strategies for patients with bladder cancer.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age 18 years or older.

• Suspected or histologically confirmed urothelial carcinoma of the bladder.

• Scheduled to undergo TURBT.

• Availability of sufficient peripheral blood samples for cfDNA extraction and mutation analysis.

• Availability of complete clinicopathological and perioperative data.

• Ability to provide informed consent and comply with study follow-up.

Locations
Other Locations
China
The Second Hospital of Lanzhou University
RECRUITING
Lanzhou
Time Frame
Start Date: 2026-04-01
Estimated Completion Date: 2027-04-01
Participants
Target number of participants: 150
Treatments
Patients Undergoing TURBT for Bladder Cancer
Adult patients with suspected or confirmed bladder urothelial carcinoma who are scheduled to undergo TURBT will be enrolled. Intraoperative irrigation fluid absorption volume, perioperative plasma cfDNA levels, mutation status, clinicopathological features, and postoperative oncological outcomes will be collected and analyzed.
Related Therapeutic Areas
Sponsors
Leads: Zhiping Wang

This content was sourced from clinicaltrials.gov

Similar Clinical Trials